The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mortality Trends in Lupus Nephritis

Mortality Trends in Lupus Nephritis

February 28, 2019 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Introduction: Systemic lupus erythematosus (SLE) is associated with multiple morbidities and premature mortality. Lupus nephritis (LN) affects ~50% of adults with SLE, and despite the introduction of improved, lower-toxicity treatments in the past 15 years, including mycophenolate and low-dose cyclophosphamide regimens (6–8), up to 30% of patients with LN develop end-stage renal disease (ESRD). Mortality among patients with SLE is highest among this subgroup. Compared with white patients, African American patients with ESRD due to LN have increased mortality, mediated in part by socioeconomic factors.

You Might Also Like
  • Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population
  • ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances

Objective: A prior study found that premature mortality among patients with ESRD due to LN persisted in the U.S. between 1995 and 2006. The present study was undertaken to extend this analysis through 2014 to examine more recent trends, including key cause-specific mortality trends.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods: Using the national registry of patients with ESRD, Jorge et al. identified all patients with incident ESRD due to LN between Jan. 1, 1995, and Dec. 31, 2014, divided into four 5-year cohorts of ESRD onset by calendar year (1995–1999, 2000–2004, 2005–2009, 2010–2014). They assessed mortality within each cohort. Temporal trends in all-cause mortality and cause-specific mortality were examined, adjusting for covariates.

Results: Jorge et al. identified 20,974 individuals with incident ESRD due to LN from 1995 through 2014. Mortality trends. A total of 4,131 patients with ESRD due to LN died during study follow-up (19.7%). The mortality rate per 100 patient-years declined from 11.1 (95% confidence interval [95% CI] 10.4–11.8) in 1995–1999 to 6.7 (95% CI 6.2–7.2) in 2010–2014 (P for trend <0.01). Adjusted mortality hazard ratios in 2010–2014, compared with 1995–1999, were 0.68 (95% CI 0.58–0.78) for white patients, 0.67 (95% CI 0.57–0.78) for African American patients, and 0.51 (95% CI 0.38–0.69) for Hispanic patients. Deaths from cardiovascular disease (CVD) and infection declined by 44% and 63%, respectively, from 1995–1999 to 2010–2014 (P for trend <0.01 for both).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Discussion: In this study of nearly all patients with incident ESRD due to LN in the U.S. over the past two decades, Jorge et al. observed a 32% reduction in mortality. These findings expanded on those in previous studies that showed no change in mortality rates from 1995 to 2006 and nonsignificant improvement from 1995 to 2010 among patients with incident LN-associated ESRD in the U.S. Similarly, they discovered a stable trend among patients with ESRD due to LN during the first 10 years (1995–2004). However, a clear trend of improvement in mortality emerged across the latest decade (2005–2014).

Pages: 1 2 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Arthritis & Rheumatology, End-stage renal disease, Lupus nephritis, mortality, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population
  • ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.